CD30 expression in follicular lymphoma

被引:1
|
作者
Gardner, LJ
Polski, JM
Evans, L
Perkins, SL
Dunphy, CH
机构
[1] St Louis Univ, Hlth Sci Ctr, Dept Pathol, Div Hematopathol, St Louis, MO USA
[2] Univ S Alabama, Dept Pathol, Mobile, AL 36688 USA
[3] Univ Utah, Hlth Sci Ctr, Hematopathol Sect, Salt Lake City, UT USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-CD30(+) anaplastic large cell lymphomas were originally described as being of T-cell, null cell, and B-cell origin. CD30, however, is not a specific marker of anaplastic large cell lymphoma and has been found to be expressed in reactive as well as neoplastic populations as a probable activation marker. In addition, CD30(+) cells have also been described in both diffuse large B-cell and follicular lymphomas (FLs), resembling the pattern seen in reactive tonsils and lymph nodes. Objective.-We report an index case of FIL with CD30 expression, which on initial touch preparations and flow cytometric immunophenotyping revealed a prominent population of CD30(+) cells with marked cellular pleomorphism (anaplasia) in a background of typical FL. Immunohistochemistry of the paraffin section for CD30 in our index case confirmed unequivocal CD30(+) pleomorphic cells in the malignant nodules in occasional clusters. This case prompted a study of additional cases of FL for pattern of immunoreactivity with CD30 on paraffin sections. Design.-Twenty-two additional cases of FL (grades 1-3) were retrieved for CD30 immunoperoxidase staining as in the index case. Results.-This study demonstrated 32% of the additional cases of FL had definitive CD30(+), large, pleomorphic malignant cells by paraffin immunohistochemistry. In 2 cases (9%), the pattern of immunoreactivity with CD30 showed clustering and variable staining of large cells, as our index case. Conclusion.-This study underscores the morphologic and immunophenotypic spectrum of FL that includes CD30 staining and cellular pleomorphism.
引用
收藏
页码:1036 / 1041
页数:6
相关论文
共 50 条
  • [31] Pilotropic CD30 positive lymphoma.
    Trémeau-Martinage, C
    Gorguet, B
    Lamant, L
    Brousset, P
    Loche, F
    Fillola, G
    Corberand, J
    Tkaczuck, J
    Bazex, J
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1999, 126 (05): : 434 - 438
  • [32] Role of CD30 Targeting in Malignant Lymphoma
    Kumar, Anita
    Younes, Anas
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 210 - 225
  • [33] Role of CD30 Targeting in Malignant Lymphoma
    Anita Kumar
    Anas Younes
    Current Treatment Options in Oncology, 2014, 15 : 210 - 225
  • [34] CD30 Expression in Non-Hodgkin B-Cell Lymphoma
    Hintzke, M.
    Fenske, T.
    Kroft, S. H.
    Olteanu, H.
    Harrington, A. M.
    LABORATORY INVESTIGATION, 2013, 93 : 331A - 332A
  • [35] CD30 expression in bladder cancer
    Cooke, PW
    James, ND
    Ganesan, R
    Wallace, M
    Burton, A
    Young, LS
    JOURNAL OF PATHOLOGY, 1999, 188 (01): : 38 - 43
  • [36] Expression of CD30 in celiac sprue
    Molina, Enrique
    Feldman, Paul
    Vincentelli, Cristina
    Martinez, Antonio
    Barkin, Jamie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S102 - S102
  • [37] CD30 expression is common in mediastinal large B-cell lymphoma
    Higgins, JP
    Warnke, RA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 112 (02) : 241 - 247
  • [38] Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
    Jagadeesh, Deepa
    Horwitz, Steve
    Bartlett, Nancy L.
    Kim, Youn
    Jacobsen, Eric
    Duvic, Madeleine
    Little, Meredith
    Trepicchio, William
    Fenton, Keenan
    Onsum, Matthew
    Lisano, Julie
    Advani, Ranjana
    ONCOLOGIST, 2022, 27 (10): : 864 - 873
  • [39] T-cell lymphoma with expression of CD30: a study of 27 cases
    Aldred, V. I.
    Zerbini, M. C. N.
    Siqueira, S. A. C.
    Castelli, J. B.
    Pereira, J.
    HISTOPATHOLOGY, 2010, 57 : 156 - 156
  • [40] CD30 Expression in Non-Hodgkin B-Cell Lymphoma
    Hintzke, M.
    Fenske, T.
    Kroft, S. H.
    Olteanu, H.
    Harrington, A. M.
    MODERN PATHOLOGY, 2013, 26 : 331A - 332A